Patients activation in people with Parkinson disease and its relation to personal factors
Objective: To identify individual factors associated with patient activation among people with Parkinson’s disease (PD). Background: The concept of patient activation captures subjective aspects of…Tremor in patients with chronic inflammatory demyelinating polyneuropathy: prevalence and severity
Objective: To determine prevalence and severity of tremor in patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Background: Tremor is an underrecognized and possibly disabling symptom…motor and non-motor correlates of hyposmia detected by the italian olfactory identification test (ioit) in an italian cohort of parkinson’s disease patients
Objective: To characterize olfaction in a cohort of PD patients and to investigate the relationship between olfactory impairment with both motor and non-motor features and other clinical characteristics…Cortical excitability of sensorimotor cortex in Parkinson’s disease-related pain
Objective: To clarify the functional role of sensorimotor cortex in Parkinson’s disease (PD)-related pain. Background: Pain is one of the most common nonmotor symptoms in…Primary CNS Lymphoma presenting with Hemichorea Hemiballismus.
Objective: Completing the list of Hemichorea Hemiballismus apart from stroke and hyperglycaemic states. Background: 61years old female presented with subacute onset abnormal irregular purposeless movements…Lysosomal-driven reduction of alpha-synuclein aggregates in a neuron-like model of Parkinson’s disease
Objective: To test whether PIKfyve inhibition results in a lysosomal-driven reduction of alpha-synuclein aggregates in a mutant neuroblastoma cell line overexpressing an aggregation-prone form of…AAV5-miHTT gene therapy mediates sustained mutant huntingtin lowering in brain and cerebrospinal fluid of Huntington’s disease minipigs up to 5 years
Objective: Our objective is to assess long-term safety of and durability of an adeno-associated viral vector serotype 5 encoding an engineered miRNA (AAV5-miHTT) targeting human…Innovating Clinical Trial Design to Accelerate Assessment of Disease-Modifying Treatments for Parkinson’s: The EJS ACT-PD Initiative
Objective: To design an optimal multi-arm, multi-stage (MAMS) platform trial for disease-modifying therapies (DMTs) in Parkinson’s disease (PD). Background: The current clinical trials process cannot…Age at Onset and Therapeutic Efficacy of Primidone in Essential Tremor Patients
Objective: To study the therapeutic response of primidone in different age groups of Essential Tremor (ET) patients, based on age at onset. Background: Essential Tremor…Design of a time-to-event study in GBA Parkinson’s Disease patients: Efficacy and safety of BIA 28-6156, an allosteric activator of beta-glucocerobridase (GCase)
Objective: To assess the efficacy of BIA 28-6156 in delaying clinically meaningful motor progression in PD patients who have a PD-risk associated variant in the…
- « Previous Page
- 1
- …
- 132
- 133
- 134
- 135
- 136
- …
- 186
- Next Page »